Answers are grounded in this paper and cite their sources.
Recombinant tissue plasminogen activator (rt-PA) is a thrombolytic agent and essential in emergency medical care. Given recent supply shortages, the availability of biosimilar products is an urgent medical need. However, biosimilarity trials are difficult to perform in critically ill patients.
No takes yet. Share an insight, caveat, or question.
Derhaschnig et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: